Servier Maroc

Servier Maroc company information, Employees & Contact Information

Explore related pages

Related company profiles:

Fondé pour servir la santé, Servier est un groupe pharmaceutique international gouverné par une Fondation, qui aspire à avoir un impact sociétal significatif pour les patients et pour un monde durable. Son modèle unique de gouvernance lui permet de servir pleinement sa vocation avec une vision à long terme : être engagé pour le progrès thérapeutique au bénéfice des patients. Les 21 900 collaborateurs qui composent le Groupe sont engagés autour de cette vocation commune, source d’inspiration au quotidien. Leader mondial en cardiologie, Servier a pour ambition de devenir un acteur focalisé et innovant en oncologie en ciblant des cancers difficiles à traiter. C’est pourquoi le Groupe consacre plus de 70 % de son budget de R&D au développement de thérapies ciblées et innovantes en oncologie. Les neurosciences et les maladies immuno-inflammatoires constituent un futur relais de croissance. Dans ces domaines, Servier se focalise sur un nombre restreint de pathologies spécifiques dans lesquelles une caractérisation précise des patients permet de proposer une réponse thérapeutique ciblée, grâce à la médecine de précision. Pour favoriser l’accès à des soins de qualité pour tous, et à moindre coût, le Groupe propose également une offre de médicaments génériques couvrant la majorité des pathologies, en s’appuyant sur des marques fortes en France, en Europe de l’Est, au Brésil et au Nigeria. Dans tous ces domaines, le Groupe intègre la voix du patient à chaque étape du cycle de vie du médicament. Servier, dont le siège social est basé en France, s’appuie sur une solide implantation géographique dans plus de 150 pays et a réalisé, en 2023, un chiffre d’affaires de 5,3 milliards d’euros. --- Si vous avez constaté ou si vous pensez être sujet à un problème de santé lié à l’utilisation d’un médicament Servier ou de tout autre produit de santé Servier, rendez-vous sur servier.com

Company Details

Employees
76
Address
Immeuble Zevaco, Lot Fath 4 Bd Abdelhadi Boutaleb (Ex. Rte D’azemmour) 20180 Casablanca, Casablanca,morocco
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Casablanca
Looking for a particular Servier Maroc employee's phone or email?

Servier Maroc Questions

News

2025 Servier R&D Day - MassBio - Massachusetts Biotechnology Council

2025 Servier R&D Day - MassBio Massachusetts Biotechnology Council

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy - Servier

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy Servier

French drug maker Servier sets up U.S. headquarters in Boston’s Seaport - statnews.com

French drug maker Servier sets up U.S. headquarters in Boston’s Seaport statnews.com

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma - PR Newswire

Servier Presents Transformational Data from Pivotal Phase 3 INDIGO Trial of Vorasidenib in Recurrent or Residual Grade 2 IDH-Mutant Diffuse Glioma PR Newswire

Servier - Massachusetts Biotechnology Council

Servier Massachusetts Biotechnology Council

7 start-ups hosted - Servier

7 start-ups hosted Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition - Servier

Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition Servier

Boston-Cambridge: a world-renowned innovation hub - Servier

Boston-Cambridge: a world-renowned innovation hub Servier

See our bases throughout the world - Servier

See our bases throughout the world Servier

Servier and Google Cloud Expand Partnership on using data and AI - Servier

Servier and Google Cloud Expand Partnership on using data and AI Servier

The Group in figures - Servier

The Group in figures Servier

Learn more about our development portfolio - Servier

Learn more about our development portfolio Servier

Our ambition for 2030 - Servier

Our ambition for 2030 Servier

Servier’s 2023 Golden Ticket at LabCentral for Hovana, Inc. - Servier

Servier’s 2023 Golden Ticket at LabCentral for Hovana, Inc. Servier

Servier x Owkin: AI-driven precision therapeutics - Servier

Servier x Owkin: AI-driven precision therapeutics Servier

Integrated annual report 2023/2024 - Servier

Integrated annual report 2023/2024 Servier

Pancreatic Cancer: Aitia and Servier will collaborate - Servier

Pancreatic Cancer: Aitia and Servier will collaborate Servier

Our commitment to oncology - Servier

Our commitment to oncology Servier

Servier is boosting its digital transformation with Google Cloud! - Servier

Servier is boosting its digital transformation with Google Cloud! Servier

Hemato-Oncology: Servier Announces Partnership with QIAGEN - Servier

Hemato-Oncology: Servier Announces Partnership with QIAGEN Servier

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer - Taylor & Francis Online

A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer Taylor & Francis Online

Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US - Fierce Biotech

Servier shells out $210M upfront to license Ideaya's potential first-in-class PKC inhibitor outside the US Fierce Biotech

Servier reveals a new visual identity - Servier

Servier reveals a new visual identity Servier

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate - Fierce Biotech

Servier supercharges neuro pipeline with $450M deal for Fragile X syndrome candidate Fierce Biotech

The Research and Development Institute in Paris-Saclay - Servier

The Research and Development Institute in Paris-Saclay Servier

Fostering a healthy environment - Servier

Fostering a healthy environment Servier

The season for hiring PhD students has officially begun at Servier! - Servier

The season for hiring PhD students has officially begun at Servier! Servier

Servier completes acquisition of Agios Pharmaceuticals’ oncology business - Servier

Servier completes acquisition of Agios Pharmaceuticals’ oncology business Servier

All our latest news - Servier

All our latest news Servier

World Cancer Day: Servier, committed to fight cancer - Servier

World Cancer Day: Servier, committed to fight cancer Servier

Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect - Fierce Biotech

Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect Fierce Biotech

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says - Fierce Pharma

Servier's beefing up in oncology through dealmaking and Tibsovo wins—and it's not done yet, U.S. CEO says Fierce Pharma

Court reverses Servier verdict on Mediator, ⁠orders payment of €430M - Fierce Pharma

Court reverses Servier verdict on Mediator, ⁠orders payment of €430M Fierce Pharma

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer - MedCity News

Big Servier Acquisition Pays Off as FDA Approves Drug for Two Types of Rare Brain Cancer MedCity News

Changing identity, Agios to sell cancer drug business to Servier - BioPharma Dive

Changing identity, Agios to sell cancer drug business to Servier BioPharma Dive

Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma - BioSpace

Servier Gets FDA Approval for First Targeted Therapy for Grade 2 IDH-Mutant Glioma BioSpace

Member Spotlight: Q&A with Servier BioInnovation (SBI) - Massachusetts Biotechnology Council

Member Spotlight: Q&A with Servier BioInnovation (SBI) Massachusetts Biotechnology Council

Servier opens Kendall Square site, plans Chinese office to access external innovation - Fierce Biotech

Servier opens Kendall Square site, plans Chinese office to access external innovation Fierce Biotech

Jacques Servier, 92, Dies; Accused of Hiding the Risks of Drugs (Published 2014) - The New York Times

Jacques Servier, 92, Dies; Accused of Hiding the Risks of Drugs (Published 2014) The New York Times

Tutorial Videos - Servier Medical Art

Tutorial Videos Servier Medical Art

Servier expands global footprint post Shire deal - pharmaphorum

Servier expands global footprint post Shire deal pharmaphorum

French drugmaker Servier ordered to pay $471m over Mediator scandal - RFI

French drugmaker Servier ordered to pay $471m over Mediator scandal RFI

Top Servier Maroc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant